Menu

1 / 2

Aurora Cannabis: Organigram Likely To Win Takeover Battle - Hold (Rating Downgrade)

All Articles on Seeking Alpha·11 days ago
#S6mBlHWq
#seekingalpha#aurora#cannabis#company#seeking
Long article (336 words) — no AI summary yet.
Reading 0:00
15s threshold

Home

Healthcare

Summary

While Aurora Cannabis faces headwinds in the domestic market, the company's business in Europe has continued to grow H1-2027.

The company's attractive valuation and strong balance sheet have attracted takeover interest from U.S. competitor Curaleaf.

In response, ACB launched a review of strategic alternatives which resulted in a superior offer from domestic competitor Organigram.

In my view, the Organigram offer delivers better value and greater flexibility for shareholders. As a result, Aurora Cannabis shareholders should consider voting for the agreement.

With the company's shares trading close to Organigram's offer, I am downgrading Aurora Cannabis stock from "Buy" to "Hold" while increasing my price target from US$4.80 to US$5.50.

I do much more than just articles at Value Investor's Edge: Members get access to model portfolios, regular updates, a chat room, and more.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.